New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

By Mariam Sunny (Reuters) -U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Novo Nordisk Foundation & Denmark invest €80M in a Microsoft-powered quantum computer to boost Nordic tech innovation.

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® ...